Acquired immunodeficiency syndrome-related lymphomas: Future directions

Seminars in Oncology

Volumn 27, Issue 4 SUPPL., 2000, Pages 454-462

  Porcu, P ^a   Caligiuri, M A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOMA; PRIORITY JOURNAL; REVIEW; VIRUS CARCINOGENESIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; HERPESVIRUS 4, HUMAN; HIV; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN;

EID: 0033887004     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Standard-dose vs. low-dose mBACOD chemotherapy for HIV-associated non-Hodgkin's lymphoma
2. Declining incidence of Kaposi's sarcomain AIDS Clinical Trial Group trials. Second National AIDS Malignancy Conference, Bethesda, 1998
3. Effect of antiretroviral therapy on the incidence of malignancies among HIV-infected persons. Second National AIDS Malignancy Conference, Bethesda, 1998
4. Declines in AIDS incidence associated with highly active anti-retroviral therapy (HAART) are not reflected in KS and lymphoma incidence. Second National AIDS Malignancy Conference, Bethesda, 1998
5. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
6. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas
7. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multi-centric Castleman's disease
8. Pathogenesis of AIDS-related lymphomas. Molecular and histogenetic heterogeneity
9. AIDS-associated non-Hodgkin's lymphoma in San Francisco
10. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University Medical Center experience with 105 patients (1981-1986)
11. Lymphomas associated with HIV infection
12. AIDS-related Burkitt's lymphoma
13. The molecular pathology of AIDS-related non-Hodgkin's lymphoma
14. AIDS-related lymphoid neoplasia: The Memorial Hospital experience
15. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy
16. Definition of two distinct types of AIDS associated non-Hodgkin's lymphoma
17. Molecular profile of Epstain-Barr virus in human immunodeficiency virus type-1 related lymphadenopathies and lymphomas
18. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr virus latent gene expression
19. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma
20. Frequent mutations of the 5' noncoding region of the BCL6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas
21. BCL-6 protein is expressed in germinal center B-cells
22. Epstein-Barr virus-specific cytotoxic T-cell responses in HIV infection
23. Differential expression of BCL-6, CD138/Syndecan-1 and EBV-encoded latent membrane protein-1 identifies distinct histogenetic pathways in AIDS-related non-Hodgkin's lymphoma
24. P53 protein over-expression and P53 gene abnormalities in HIV-1-related non-Hodgkin's lymphoma
25. Frequency of prolonged remission duration after high-dose cytarabine intensification varies by cytogenetic subtype
26. Direct polyclonal activation of human B-lymphocytes by the AIDS virus
27. Induction of IL-6 production by human immunodeficiency virus
28. Human immunodeficiency virus type-1 TAT protein activates B-lymphocytes
29. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells
30. Upregulation of IL-6 receptor (CD126) expression on monocytes, B-lymphocytes, and CD4 T-lymphocytes in HIV infection
31. Human immunodeficiency virus-1 (HIV-1) Tat protein promotes migration of acquired immunodeficiency sybdrome-related lymphoma cells and enhances their adhesion to endothelial cells
32. Complete remission of primary effusion lymphoma with antiretroviral therapy
33. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy
34. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
35. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
36. Opportunistic infections and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy
37. Concomitant CHOP chemotherapy and highly active antiretroviral therapy in patients with HIV-related non-Hpodgkin's lymphoma
38. The use of new antiretroviral therapy in combination with chemotherapy
39. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin-2
40. Molecular mimicry of human cytokine and cytokine pathway genes by KSHV
41. Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue
42. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologues which are expressed in Kaposi's sarcoma and malignant lymphomas
43. Expression of cell-homologous genes of human herpesvirus-8 in human immunodeficiency virus-negative lymphoproliferative diseases
44. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus-8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease
45. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors
46. Immune escape of tumors in vivo by expresion of cellular FLICE-inhibitory protein
47. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
48. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
49. Apoptosis control by death and decoy receptors
50. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma
51. Etiology of cancer: Viruses
52. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation
53. Epstein-Barr virus lymphoproliferation after bone marrow transplantation
54. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorder
55. The clinical diversity and role of chemotherapy in lymphoproliferative disorders in liver transplant patients
56. Post-transplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression
57. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: Two cases after solid organ transplantation
58. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease
59. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplant lymphoproliferative disorders
60. Immunodeficiency-associated lymphoproliferative disorders
61. Chemokine receptor trafficking and viral replication
62. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: Withdrawal of chemokines from the environment of cytomegalovirus-infected cells
63. Human herpesvirus KHSV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation
64. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
65. Clinico-pathologic, immunophenotypic, and molecular genetic analysis of AIDS-associated lymphoid neoplasia. Clinical and biological implications
66. Pathogenesis of B-cell lymphoma in patients with AIDS
67. Chemokine and chemokine-receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiciency virus-1-infected individuals
68. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-Δ35 mutation
69. Homozygous defects on HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
70. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene
71. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study
72. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1α, and MIP-1β
73. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
74. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
75. The chemokine SDF-1, stromal cell-derived factor-1, attracts early stage B-cell precursors via chemokine receptor CXCR4
76. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine receptor variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MHCS), San Francisco City Cohort
77. Risk factors for non-Hodgkin's lymphomas in acquired immunodeficiency syndrome (AIDS)
78. + T cell expansion during regression of monoclonal EBV-associated post-transplant lymphoproliferative disorder
79. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
80. Immune reconstitution in AIDS
81. Thymic function can be accurately monitored by the level of recent T-cell emigrants in the circulation
82. Changes in thymic function with age and during the treatment of HIV infection
83. Viral immune evasion due to persistence of activated T-cells without effector functions
84. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
85. HIV-induced immunopathogenesis
86. A review of the association between interleukin-10 and human B-cell malignancies
87. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10
88. Immunotherapy with low-dose interleukin-2: Rationale for prevention of immune-deficiency-associated cancer
89. Low-dose interleukin-2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in SCID/SCID mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes
90. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
91. + T-cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
92. Prognostic factors in the treatment of human immunodeficiency virus-1-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142 - Low vs. standard dose mBACOD plus granulocyte-macrophage colony stimulating factor
93. Daily subcutaneous injection of low-dose interleukin-2 expands natural killer cells in vivo without significant toxicity
94. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high-affinity receptors
95. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
96. HLA-peptide tetrameric complexes
97. + T cells using an ELISPOT assay